Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 1,391 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study Pill Clear all

Conditions: Schizophrenia
Interventions: Lurasidone, Olanzapine, Placebo comparator, Lurasidone 40 mg tablets; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 25
States / cities: Little Rock, Arkansas • Cerritos, California • Oceanside, California + 20 more

Conditions: Alcohol Use Disorder (AUD)
Interventions: Suvorexant 20 mg, Placebo oral tablet; Drug
Lead sponsor: The Scripps Research Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Alcohol Use Disorder
Interventions: Probenecid or placebo single administration; Drug
Lead sponsor: Brown University; Other
Eligibility: 21 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Cocaine Addiction, Cocaine Abuse, Cocaine Dependence, Substance Abuse
Interventions: Placebo, Doxazosin; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Post-operative Pain Control
Interventions: Oxycodone Pill A, Oxycodone Pill B; Other
Lead sponsor: Mount Carmel Health System; Other
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Parkinson's Disease
Interventions: Sinemet 25-100 Oral Tablet, XP21279, Carbidopa Pill; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Peoria, Arizona • Bingham Farms, Michigan

Conditions: Posttraumatic Stress Disorder, Alcohol Use Disorders
Interventions: doxazosin, placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Menopause, Arteriosclerosis
Interventions: Conjugated equine estrogens 0.45 mg/day, Transdermal estradiol, 50 mcg/day, Micronized progesterone, 200 mg/day x 12 d/month, CEE , progesterone, estradiol patch or placebo for each, CEE, progesterone, transdermal patch or the placebo; Drug
Lead sponsor: Kronos Longevity Research Institute; Other
Eligibility: 42 Years to 58 Years · Female only
Enrollment: 728 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2012
U.S. locations: 9
States / cities: Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 6 more

Conditions: Anxiety in Those Patients With Anorexia Nervosa, Eating Disorder Not Otherwise Specified, BMI (<=18)
Interventions: Hydroxyzine, hydroxyzine HCL, Placebo; Drug · Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 8 Years to 25 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Urinary Retention
Interventions: Tamsulosin 0.4Mg Capsule, Placebo oral tablet; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Depression
Interventions: Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro), Placebo, Interpersonal Clinical Interaction (ICI); Drug · Other · Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pain, Burn Injury
Interventions: Gabapentin, Placebo; Drug
Lead sponsor: Lucy A Wibbenmeyer; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Spinal Muscular Atrophy
Interventions: 4-aminopyridine, Placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Cardiomyopathy, Heart Failure
Interventions: POMx, pomegranate polyphenol extract, Sugar Pill; Drug
Lead sponsor: Jennifer Cowger , MD, MS; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Ann Arbor, Michigan

Conditions: Phobias
Interventions: D-cycloserine, Placebo; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Overweight, Obesity
Interventions: NNC0662-0419, Oral contraceptive, Acetaminophen; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Mucosal Melanoma, Acral/Lentiginous Melanoma, Chronically Sun Damaged Melanomas
Interventions: Imatinib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 5
States / cities: Denver, Colorado • Tampa, Florida • Chicago, Illinois + 2 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Placebo, Study Medication (MBX-2982), No medication for this group; Drug · Other
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 20 Years to 60 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: HIV Infections, Sexually Transmitted Diseases
Interventions: PrEPmate, Dot Diary; Other · Device
Lead sponsor: Public Health Foundation Enterprises, Inc.; Other
Eligibility: 15 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: San Francisco, California • Washington D.C., District of Columbia • Miami, Florida

Conditions: Alcohol Dependence, Anxiety
Interventions: Doxazosin, Placebo; Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Providence, Rhode Island

Conditions: Gout
Interventions: placebo, BCX4208; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 24
States / cities: Scottsdale, Arizona • Tucson, Arizona • Irvine, California + 21 more

Conditions: Alopecia Areata
Interventions: Apremilast, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Orthostatic Hypotension, Parkinson's Disease
Interventions: Droxidopa, Placebo; Drug · Other
Lead sponsor: Chelsea Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 60
States / cities: Alabaster, Alabama • Gilbert, Arizona • Phoenix, Arizona + 53 more

Conditions: Other Disorders of Bone Development and Growth
Interventions: Combined Oral Contraceptive (COC), Contraceptive Vaginal Ring (CVR); Drug
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 25 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: University Park, Pennsylvania

Search by objective public record fields.

Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia

Medication Development in Alcoholism: Suvorexant Versus Placebo

Probenecid as Medication for Alcohol Use Disorder (PROB)

The Effects of Doxazosin on the Cardiovascular and Subjective Effects of Cocaine

Impact of the Number of Opiates Prescribed on Post Cesarean Pain Control

An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects

CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders

Kronos Early Estrogen Prevention Study (KEEPS)

Does Hydroxyzine Decrease Anxiety in Underweight Patients Diagnosed With an Eating Disorder

Preoperative Tamsulosin to Prevent Postoperative Urinary Retention After Surgery For Pelvic Floor Disorders

Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression

The Effect of Neurontin on Pain Management in the Acutely Burned Patient

Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients

The Impact of Pomegranate Extract on Chronic Cardiomyopathy Complicated by Renal Insufficiency (ImPrOVE): a Pilot Study

fMRI Study Examining Effects of D-cycloserine in Specific Phobia

A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight

Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma

GPR119 Agonist for Hypoglycemia in Type 1 Diabetes

Comparing Mobile Health Strategies to Improve Pre-exposure Prophylaxis Use (PrEP) for HIV Prevention

Doxazosin an a1 Antagonist for Alcohol Dependence

Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout

Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata

A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease

Assessing the Impact of Contraceptives on Bone Health Using 41Ca